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ABSTRACT
PEA3, ERM and ER81 belong to the PEA3 subfamily of
Ets transcription factors and play important roles in a
number of tissue-specific processes. Transcriptional
activation by PEA3 subfamily factors requires their
characteristic amino-terminal acidic transactivation
domain (TAD). However, the cellular targets of this
domain remain largely unknown. Using ERM as a
prototype, we show that the minimal N-terminal
TAD activates transcription by contacting the activa-
tor interacting domain (ACID)/Prostate tumor
overexpressed protein 1 (PTOV) domain of the
Mediator complex subunit MED25. We further show
that depletion of MED25 disrupts the association of
ERM with the Mediator in vitro. Small interfering
RNA-mediated knockdown of MED25 as well as the
overexpression of MED25-ACID and MED25-VWA
domains efficiently inhibit the transcriptional
activity of ERM. Moreover, mutations of amino acid
residues that prevent binding of MED25 to ERM
strongly reduce transactivation by ERM. Finally we
show that siRNA depletion of MED25 diminishes
PEA3-driven expression of MMP-1 and Mediator
recruitment. In conclusion, this study identifies the
PEA3 group members as the first human transcrip-
tional factors that interact with the MED25 ACID/
PTOV domain and establishes MED25 as a crucial
transducer of their transactivation potential.
INTRODUCTION
The Ets transcription factors are regulatory proteins
involved in cancer, cell growth and differentiation. All
Ets proteins contain a DNA-binding domain (ETS
domain) of 85 amino acids that enables them to bind
to GGAA/T sites (1). Functional domains and post-
translational modifications lying outside the highly
conserved ETS domain provide the potential for individ-
ual Ets proteins to exhibit unique properties (1).
The human ERM protein belongs to the PEA3 subfam-
ily of Ets proteins (2) and contains at least four functional
domains (Figure 1A): an amino-terminal transactivation
domain (TAD; residues 1–72) (3,4), a central negative
regulatory domain (NRD; residues 73–298) (5,6), the
carboxy-terminal ETS domain (residues 363–451) and a
carboxy-terminal TAD (residues 452–510) (4). Initial
experiments demonstrated that the first 72 residues and
the carboxy-terminal tail constituted transferrable activa-
tion domains (4). Subsequent experiments demonstrated
that the amino-terminal TAD is regulated by a flanking
NRD, which functions in a sumoylation-dependent
manner (5,6). The amino-terminal activation domain is
highly conserved (85% sequence identity) among
PEA3 subfamily members and represents the main activa-
tion domain of all three proteins (3,4,7,8). The TAD from
the protein ERM displays minimal stable tertiary struc-
ture (9), and the combination of acidic and hydrophobic
amino acids within this domain appears similar to that
found in the TADs of other activators such as the
herpes simplex viral protein 16 (VP16) (10,11).
Despite the importance of the ERM TAD, mechanistic
details of how it interacts with other proteins and operates
at a molecular level are limited. It is thought that the
ERM TAD participates in interactions with transcrip-
tional cofactors (3). However, a direct ERM TAD inter-
acting protein within the RNA polymerase II general
transcription machinery has not yet been reported.
In this article, we identify the Mediator complex subunit
MED25 as a direct physical target and functional partner
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Figure 1. ERM binds to MED25. (A) Schematic summary of the interaction between ERM and MED25 proteins. The N-terminal TAD of ERM
interacts with the ACID of MED25. NR: Nuclear receptor box. Numbers refer to amino acid. (B) Deletion analysis of ERM shows that the
N-terminal 38–72 domain is sufficient for binding MED25 in vitro. GST fusion proteins of the indicated ERM fragments were used to assess the
binding to full-length rabbit reticulocyte lysate in vitro generated Flag-MED25. Binding was detected by autoradiography (upper panel) or immuno-
blotting with anti-Flag (bottom panel). An SDS gel stained with Coomassie showing the expression of the GST fusion proteins is shown.
(C) Deletion analysis of MED25 shows that the ACID domain is sufficient for binding to ERM 38–72 in vitro. GST and GST-ERM 38–72 were
incubated with the indicated MED25 fragments produced in reticulocyte lysate. Binding was detected by immunoblotting with anti-Flag or anti-GFP.
(D) Co-immunoprecipitation of MED25 with ERM. Flag-MED25 and wild-type or mutants ERM (upper panel) or mutants Flag-MED25 together
with full-length ERM (bottom panel) were expressed in RK13 cells. Cellular extracts were immunoprecipitated with anti-Flag antibody (IP a Flag)
and immunoblotted with anti-Flag (IB a Flag) and anti-ERM (IB a ERM) antibodies. Aliquots of the same extracts were analysed with the same
antibodies to detect exogenous proteins (cellular extract). (E) Interaction between endogenous proteins. MDA-MB 231 nuclear extracts were sub-
jected to immunoprecipitation with anti-Gal4 DBD (IP Ctrl) or anti-ERM (IP ERM) antibodies. Interactions were detected by western blot using
polyclonal anti-MED25 (IB a MED25) or polyclonal anti-ERM (IB a ERM).
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of the ERM TAD. The Mediator is an evolutionary
conserved multi-subunit RNA polymerase II transcrip-
tional regulator complex critical for the tight control of
gene expression (12). The MED25 subunit is found exclu-
sively in higher eukaryotes (13) and has been shown to
link the Mediator to many viral proteins such as VP16,
IE62 and Lana-1 (14–17). In mammals, MED25 supports
the activation of transcription by several transcription
factors, including the retinoic acid receptor RARa (18),
the orphan receptor HNF4a (19) and the chondrogenic
factor Sox9 (20). Our findings identify ERM as the first
nuclear transcription factor partner of the MED25
activator interacting domain (ACID) and suggest that
the Mediator complex is an important cofactor for the
PEA3 group member activity.
MATERIALS AND METHODS
Plasmid construction
The pSG5 expression vectors encoding full-length ERM,
ETV1, ER81, PEA3 as well as ERM Nt (ERM 87–510)
and ERM Ct (ERM 1–449) have been described previ-
ously (21–23), as have the GST fusion protein expression
vectors PGEX ERM 1–510, ERM 1–370, ERM 1–122,
ERM 1–72, ERM 354–510 (21,24,25). ERM 1–38, ERM
38–72 and ERM 38–68 were amplified by PCR and
cloned into the PGEX-6P1 vector. The pCI-neo Flag
human MED25 expression plasmid was a gift from
M. Meisterernst (14). The MED25 mouse cDNA ORF
was obtained from OriGene. The human and mouse
MED25 cDNAs were subcloned into the pCDNA3 vector
with an N-terminal Flag epitope tag. All other derivatives
of MED25 correspond to the human factor unless other-
wise indicated and were generated by PCR using MED25
cDNA as template. The siRNA-resistant MED25 expres-
sion vectors were generated by replacing the ACID/PTOV
domain of human origin by its murine homologue. The
pcDNA3-NLS-EFGP vector was constructed by inserting
the open reading frame of NLS-GFP from the pNLS-
EGFP vector into the pcDNA3 vector. The ACID/PTOV
domain of human MED25 was subcloned into pcDNA3-
NLS-EGFP. The ERM activation domain derivatives
(1–72, 1–38, 38–72), E1A 13S and E2F were subcloned
into pBIND (Gal4 DNA-binding domain) vector
(Promega). The reporter plasmid (Gal4)5-E1B luc has
been described (26). The bacterial expression plasmid
encoding Halo-Tag ERM 1–72 (pET24d-Halo-Tag ERM
1–72) was generated by co-ligating the PCR amplified
Halo-Tag [template pFN22K (Promega)] and ERM 1–72.
To insert pointmutations in our respective vectors (MED25
Q451E, MED25 M470A, ERM F47L and ERM 1–72
F47L), we used the Quickchange site-directed mutagenesis
kit from Stratagene following the manufacturer’s direc-
tions. All clones were verified by sequencing. Primers
sequences and detailed procedures are available on request.
Protein expression and purification
The MED25 ACID/PTOV domain was purified as previ-
ously described (27). GST, GST ERM derivatives (1–510,
1–370, 1–122, 1–72, 354–510, 1–38, 38–72) or GST ACID
were expressed in Escherichia coli strain BL21 (DE3), and
soluble lysates were prepared as described previously
(4,21,28). Recombinant Halo-Tag, Halo-Tag ERM 1–72
and Halo-Tag ERM 1–72 F47L were purified in E. coli
according to the manufacturer’s instructions (Promega).
The purification of the ERM 38–68 peptide will be
described elsewhere. Recombinant MED25 was expressed
and radiolabelled with 35S-methionine by coupled in vitro
transcription–translation reactions (TNTT7 quick coupled
transcription–translation system Promega). Flag-MED25,
Flag-MED25 ACID, GFP, GFP ACID, Flag-MED25
Q451E, Flag-MED25 M470A, Flag-ERM and Flag-ERM
F47L were expressed by coupled in vitro transcription–
translation reactions and detected by western blot with
anti-Flag, anti-GFP or anti-ERM antibodies.
Pull-down assay
The interaction between MED25 and ERM was measured
in GST or Halo-Tag pull-down assays. In vitro translated
proteins were incubated with GST derivatives immobilized
on glutathione-sepharose beads or Halo-Tag derivatives
immobilized on HaloLink Magnetics beads (Promega),
washed, eluted and bound proteins resolved by 10%
SDS-PAGE followed by autoradiography or immunoblot-
ting as described previously (28).
Antibodies
Anti-Flag M2 antibody was purchased from Sigma and
anti-GFP monoclonal from Roche. Anti-MED14
(anti-CRSP2/DRIP150, A301-044A), anti-MED24 (anti-
TRAP100/MED24, A301-472A) and anti-MED1 (anti-
CRSP1/TRAP220, A300-793A) were purchased from
Bethyl Laboratories, anti-MED6 (sc-9434) and anti-Gal4
DBD (sc-577) from Santa Cruz. Rabbit antisera were
generated against the human MED25 ACID domain by
Covalab. Anti-ERM has been previously described (21).
Cell culture and transfection
RK13, U2OS, MDA-MB 231 and MCF-7 cells were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS (Gibco BRL).
DAMI (HEL) cells were cultured in IDMEM (Iscove’s
modification of DMEM) supplemented with 10% horse
serum. In six-well plates, 1.5 105 cells/well were plated,
and the next day, transfections were performed using the
PEI Exgen 500 procedure (Euromedex, France). For
co-immunoprecipitation experiments, 150–250 ng of
PEA3 group expression plasmid and/or 200–300 ng of
MED25 plasmid were used. For MED25 overexpression
assays, cells were cotransfected with 10 ng of ERM expres-
sion vector with increasing concentrations (0.5, 1, 2.5 and
5 ng) of MED25 expression vectors [MED25 full-length,
ACID domain or Von Willebrand factor A domain (VWA
domain)]. Nuclear extracts of DAMI were prepared as
previously described (28).
Luciferase assay
The activities of GAL-ERM derivatives were assayed
using the dual-luciferase reporter assay system
(Promega) as described previously (29).
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Co-immunoprecipitation
Transfected cells were lysed in co-immunoprecipitation
buffer (50mM Tris/HCl, pH 7.5, 150mM NaCl, 0.2mM
EDTA, 1mM DTT, 1mM PMSF, 0.5% Triton X100).
Proteins were immunoprecipitated overnight with the
anti-FLAG M2 affinity gel (Sigma) at 4C. Detection of
immunoblotted target bands was performed with
anti-ERM (21) and anti-Flag (Sigma) antibody. For inter-
action between endogenous proteins, MDA-MB 231
nuclear extracts were subjected to immunoprecipitation
with anti-Gal4 DBD (Santa Cruz sc-577) or anti-ERM
(Santa Cruz sc-100941) antibodies. Interactions were
detected by western blot using polyclonal anti-MED25
or polyclonal anti-ERM (21).
Chromatin immunoprecipitations
Chromatin immunoprecipitation (ChIP) assays with
MDA-MB 231 cells (2 106) were performed as
described (26) using the EZ ChIp Kit (Millipore).
Sonicated chromatin was incubated at 4C overnight
with 5 mg of rabbit control IgG or specific antibodies.
Antibodies used were as follows: MED1 (IHC-00149
Bethyl) and MED18 (IHC-00181 Bethyl).
Immunoprecipitated and input material was analysed by
quantitative PCR. ChIP signal was normalized to total
input. The primers used for amplification of the 1607
Ets element in the human MMP-1 promoter were previ-
ously described (30).
Isothermal titration calorimetry
The equilibrium dissociation constant of the MED25
ACID-ERM 38–68 interaction was determined using an
iTC200 calorimeter (MicroCal). The binding enthalpies
were measured at 25C in 20mM sodium phosphate pH
6.5, 150mM NaCl, 5mM b-mercaptoethanol, 0.25mM
EDTA. The concentration of the MED25 ACID domain
in the cell (10mM) was roughly 10 times the estimated Kd,
and the concentration of the ERM 38–68 peptide
(100mM) in the syringe was ten times that in the cell.
Data were processed using Origin 7 software
(OriginLab) and fitted the single-binding site mechanism
with 1:1 stoichiometry.
siRNA
Cells were transfected with siRNA using INTERFERin
(Polyplus) and/or retransfected with expression
vector 18 h later with PEI or Fugene HD according to
the manufacturer’s instructions. SMART pools
(Dharmacon) were used to knockdown MED25, PEA3,
ER81 and ERM.
Quantitative real-time PCR analysis
Total cellular RNA was isolated by Illustra TriplePrep
extraction kit (GE Healthcare) or by Trizol (Molecular
research Center)/RNeasy kit (Qiagen) following the
manufacturer’s instructions. Reverse-transcription was
performed with High Archive cDNA kit (Applied
Biosystems) on extracted RNA after DNase treatment as
previously described (28). This cDNA template was PCR
amplified and copy number was determined with the
SYBRgreen qPCR master mix (Applied) on Stratagene
Mx3005P instrument. Primers sequences are available on
request.
RESULTS
ERM interacts with the Mediator complex subunit
MED25
Recently, we and others determined the solution structure
of the Mediator subunit MED25 ACID/PTOV domain
and defined the region contacted by the VP16 TAD
(27,31,32). Interestingly, the VP16 TAD contains a
region with significant homology to the TAD of ERM
(Supplementary Figure S1A). Based on this finding, we
hypothesized that ERM may interact with MED25.
Figure 1A shows the structure of ERM deletion mutants
and summarizes their behaviour in pull-down and trans-
fection assays. Binding studies were first performed using
resin bound GST and GST-ERM deletion mutants with a
panel of MED25 truncation fragments (Figure 1B and
1C). Full-length MED25 was retained with full-length,
1–370, 1–122, 1–72 and 38–72 ERM GST fusion
proteins but not with 1–38, 354–510 or the GST control
(Figure 1B). Conversely, deletion of the MED25 ACID
domain completely abolished the interaction with
GST-ERM 38–72, while the ACID domain alone was suf-
ficient to mediate the interaction (Figure 1C). Taken
together, these experiments clearly demonstrated that the
ERM TAD, like the VP16 TAD, can interact with
MED25 and mapped their reciprocal binding domains
to regions that include the ACID/PTOV domain of
MED25 and the ERM 38–72 region.
To shed more light on the biochemical interaction
between ERM and MED25, we next determined by
isothermal titration calorimetry the dissociation
constant (Kd) for the complex formed between an
ERM 38–68 peptide and the MED25 ACID/PTOV
domain. In this assay, ERM bound MED25 with an
apparent Kd value of 543 nM±40 (Supplementary
Figure S2), confirming that this is a direct interaction.
Interestingly, this binding constant lies between what
has been previously reported for VP16 H1 binding to
MED25 (1.6 mM) and that reported for VP16 H1+H2
(50 nM) (31).
We then sought to test whether the interaction between
ERM and MED25 occurred in the context of mammalian
cells using co-immunoprecipitation experiments. When
MED25 was recovered with Flag antibody, ERM was
efficiently retained (Figure 1D). Interestingly, an ERM
derivative (ERM Ct) containing the TAD retained the
ability to interact with MED25, whereas a truncated ERM
that lacked the TAD (ERM Nt) did not (Figure 1D,
upper panel). Conversely, deletion of the N-terminal or
the C-terminal domains of MED25 (MED25 Nt and
MED25 Ct, respectively) had no effect on the inter-
action, whereas deletion of the ACID domain (MED25
ACID) completely abolished the interaction with ERM
(Figure 1D, bottom panel). These results are consistent
with the in vitro pull-down assays showing that full-length
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ERM associates with full-length MED25 and that the
ERM TAD is primarily responsible for the association
with the ACID domain of MED25. Importantly, this
interaction was further verified by showing that endo-
genous MED25 co-immunoprecipitates with an ERM
antibody from MDA-MB 231 nuclear extracts
(Figure 1E). Moreover, as the amino-terminal activation
domain of all three PEA3 family members are highly
conserved, we tested and confirmed that MED25 could
also bind to PEA3, ETV1 and its spliced variant ER81
(Supplementary Figure S3).
Based on deletion analysis, the N-terminal TAD of
ERM lies within the first 72 amino acids (Figure 1A)
(3,4). To test if this domain can be divided into sub-
domains, we determined if ERM 1–38 and ERM 38–72
are capable of activating transcription when tethered
to the Gal4 DNA-binding domain. We found that only
ERM 38–72 retained the ability to stimulate transcription
(Supplementary Figure S1B), suggesting that the minimal
TAD at the N-terminal portion of ERM maps between
amino acids 38 and 72. Taken together, these results
indicate that the MED25 binding interface colocalizes
well with the minimal TAD of ERM.
Mutational studies of the interaction between
ERM and MED25
Because the residues of ERM 38–72 that form the MED25
interface display sequence homology with the VP16 H1
subdomain (Supplementary Figure S1A), we anticipated
that mutations affecting the MED25/ERM and MED25/
VP16 complexes would exhibit similar behaviours and
indeed, found this to be the case. First, a MED25 point
mutant (Q451E) that has been shown previously to
abolish MED25/VP16 interaction (31) also greatly com-
promised the ability of MED25 to interact with ERM
TAD in GST pull-down assay and in co-immunopre-
cipitation experiments (Figure 2A). Conversely, an
M470A mutation that had no effect on ERM binding
(Figure 2A), similarly failed to impair VP16 binding
(data not shown). In addition, the MED25 ACID
domain by itself or full-length MED25 failed to bind a
mutated ERM activation domain where the F47 residue
was changed to leucine (Figure 2B). It is notable that the
mutation of this residue strongly impaired ERM transac-
tivation (3) (Supplementary Figure S1B). Remarkably,
the corresponding residue in VP16 H1 (F442, see
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Figure 2. Effect of mutations in the ERM/MED25 interface. (A) Mutation of Q451 of MED25 severely reduces its ability to bind to ERM.
(Left) GST ERM 38–72 was used to analyse the binding to full-length Flag-MED25 WT and point mutants Q451E and M470A. Q451E
shows weak binding to ERM 38–72. Binding was detected by immunoblotting with anti-Flag. An SDS gel stained with Coomassie showing
the expression of the GST fusion proteins is shown. (Right) Wild-type Flag-MED25 or MED25 with a Q451E mutation were examined for
their ability to interact with ERM in co-immunoprecipitation experiments. RK13 cells were transfected with the indicated expression vectors
and cellular extracts were IP a Flag and IB a Flag. Expression of Flag-MED25, Flag-MED25 Q451E and ERM are shown in the top two
panels. (B) Mutation of F47 of ERM abolishes the recruitment of MED25. (Left) GST MED25 ACID domain was examined for its ability
to interact in vitro with ERM wild type or ERM F47L mutant. (Right) The ability of Flag-MED25 to interact with ERM wild type and
with ERM F47L mutant was analysed in co-immunoprecipitation experiments. Cells were transfected with the indicated expression vectors and
cellular extracts were IP a Flag and IB a Flag or IB a ERM (IB). Expression of Flag-MED25, ERM and ERM F47L are shown in the top panel
(cellular extract).
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Supplementary Figure S1A) has previously been shown to
be critical for the transactivation function of VP16 (10)
and for the recruitment of MED25 (14,15,33). Our results
thus demonstrate that MED25 binds only to a functional
ERM TAD.
ERM binds Mediator through MED25
To determine whether the ERM TAD interacts with intact
Mediator, we incubated nuclear extracts of DAMI cells
with purified Halo-Tag ERM 1–72 coupled to magnetic
beads. Unbound Mediator subunits present in the super-
natant after incubation (U for unbound) and beads-bound
Mediator subunits (B for bound) were then monitored by
immunoblotting with antibodies to the subunits indicated
in the figure (Figure 3). Firstly, endogenous MED25 could
be almost completely depleted from the nuclear extracts
after incubation with Halo-Tag ERM 1–72 but not with
Halo-Tag alone, confirming that ERM interacts very effi-
ciently with MED25 (Figure 3A). Notably this depletion
was not seen when we introduced a mutation in ERM
(ERM 1–72 F47L) that prevents MED25 binding
(Figure 2B). Accordingly, endogenous MED25 was only
detected in the fraction bound to wild-type ERM 1–72
(Figure 3B). Secondly, we observed that MED1 and
MED6 bound Halo-Tag ERM 1–72 but not Halo-Tag
alone, thus revealing a specific association of ERM with
Mediator (Figure 3B). Importantly, as expected, incuba-
tion with the mutant ERM 1–72 F47L impaired the inter-
action between Mediator and ERM (Figure 3B). Finally,
when the nuclear extracts were sequentially incubated
with ERM 1–72, we observed a strong correlation
between depletion of MED25 and decrease in MED1,
MED6, MED14 and MED24 binding (Figure 3C,
compare B1, B2 and B3).
To exclude the possibility that ERM 1–72 may still be
able to bind substoichiometric amounts of Mediator
subunits, we also used immunodepletion assays
(Figure 3D). Briefly, DAMI nuclear extracts were first
depleted using polyclonal antibodies against MED25
followed by incubation with Halo-Tag ERM 1–72, and
ERM-bound Mediator was detected as in Figure 3C. As
expected, immunodepletion of MED25 specifically
removed the majority of MED25 from the supernatant
but left behind other Mediator subunits (Figure 3D,
compare lane 1 with lane 2). Again, a good correlation
between depletion of MED25 and decrease binding of
Mediator subunits to ERM was observed (Figure 3D,
compare lane 3 with lane 4). Importantly, as evidenced
by the lack of change in the relative levels of Mediator
subunits expression in the unbound fraction, the inhib-
ition of Mediator recruitment appears to be specifically
caused by MED25 depletion (Figure 3D, lanes 5 and 6).
Taken together, these results clearly indicate that ERM
physically associates with Mediator through the MED25
subunit.
ERM functionally interacts with MED25
To investigate whether the interaction between ERM and
MED25 is functionally important, we first examined the
influence of MED25 expression on the transactivation
activity of ERM TAD 1–72 tethered to the Gal4 DNA-
binding domain. It has been reported that overexpression
of Mediator subunits can result in the inhibition of tran-
scription owing to competition between the overexpressed
subunits and the Mediator complex for the transcriptional
activator (15,17,34,35). In agreement with these results,
ectopic expression of MED25 efficiently inhibited the
transcriptional activity of ERM TAD (Figure 4A). By
contrast, overexpression of MED25 had no influence
on the transcriptional activity of the transcription factor
E2F or the Adenovirus E1A protein (Figure 4A), the
established target of which in Mediator is MED23 (34).
Thus, the influence of MED25 in this context appears to
be specific to ERM. Similar interference was observed
with two MED25 truncated fragments VWA and ACID
(Figure 4B), suggesting that the Mediator-binding domain
(VWA) and the ERM-binding domain (ACID) of MED25
are functionally important for mediating the transcrip-
tional activity of ERM. Interestingly, this behaviour of
ERM is reminiscent of the reported effects of MED25
on VP16 transcriptional activity (14). We also sought
to test if full-length ERM activity is affected by MED25
and chose the well-known Ets-responsive TORU-
luciferase reporter construct (36). We found that
full-length MED25 as well as MED25-VWA and
MED25-ACID domains significantly reduced ERM tran-
scriptional activity (Figure 4C). These results were in
total agreement with those obtained with the Gal4
fusions used above.
To further examine the functional role of MED25, we
next used siRNA knockdown. Transient transfection of
MED25-specific siRNA into U2OS cells resulted in an
80–90% reduction of MED25 mRNA (data not shown)
and significant depletion of protein levels (Figure 4D,
Inset). Remarkably, this depletion significantly reduced
Gal4-ERM 1–72 mediated transactivation (Figure 4D,
left panel), whereas activity of the Gal4-E2F construct
was not affected (Figure 4D, right panel). To confirm
that MED25 mediates transactivation through direct
interaction with ERM, we assessed the respective abilities
of siRNA-resistant version of MED25 derivatives (WT,
ACID, Ct, Nt, Q451E and M470A) to rescue the
transactivation potential of ERM TAD in MED25-
depleted cells (Figure 4D). When expressed at equivalent
levels, MED25 WT, MED25 M470A and MED25 Ct,
but not ERM-binding defective MED25 (ACID and
Q451E) and Mediator-binding defective MED25 (Nt),
elicited efficient rescue of ERM-directed transactivation
(Figure 4D). Taken together, these findings preclude a
non-specific off-target effect and confirm that a MED25-
containing Mediator complex is specifically required for
full transactivation by ERM TAD.
MED25 mediates PEA3-dependent gene expression
To evaluate the role of MED25 as a regulator of PEA3-
dependent gene expression, we monitored the effect of
MED25 depletion on PEA3-driven expression of two
genes identified as targets of PEA3 members (24,37,38),
namely MMP-1 and ICAM-1 (Figure 5). As a first func-
tional approach, we used MCF-7 breast cancer cell line,
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Figure 3. MED25 mediates the interaction between ERM and Mediator. (A) Depletion of endogenous MED25 from DAMI cell nuclear extract
using Halo-Tag fusion protein ERM 1–72. Nuclear extracts from DAMI cells were incubated with immobilized Halo-Tag, Halo-Tag ERM 1–72 and
Halo-Tag ERM 1–72 F47L. After incubation and extensive washing, MED25 not associated with ERM 1–72 present in the supernatant was saved as
the unbound fraction (U). Samples were separated by SDS-PAGE, and MED25 was detected by immunoblotting with anti-MED25 antibody. I:
Input, 10% of the nuclear extracts used in binding reactions. U: Unbound, 10%. (B) MED25 and Mediator (here documented with MED1 and
MED6) bind specifically to ERM 1–72. Nuclear extracts from DAMI cells were incubated with immobilized Halo-Tag, Halo-Tag ERM 1–72 and
Halo-Tag ERM 1–72 F47L as in Figure 3A. ERM 1–72-bound Mediator complex (B) was eluted by boiling the beads in SDS buffer and was
resolved by 12% SDS-PAGE before western blot analysis using the specified antibodies. I: input, 10% of the nuclear extracts used in binding
reactions. B: bound material, 100%. (C) MED25 depletion of nuclear extract impairs recruitment of Mediator to ERM. Nuclear extracts from
DAMI cells were sequentially incubated with Halo-Tag ERM 1–72 as indicated. After incubation and extensive washing, the supernatant (containing
unbound material, U1, U2 and U3) and the affinity resin (containing bound material, B1, B2 and B3) were boiled in SDS buffer and resolved by
SDS-PAGE. Specifically bound and unbound proteins were detected by western blot using the specified antibodies. I: input, 10%. U: unbound, 10%.
B: bound, 100%. (D) MED25 immunodepletion reduces interaction between ERM and Mediator. Anti-MED25 antibody and non-specific anti-serum
(control) were first coupled to Pureproteome protein A magnetic beads (Millipore). Nuclear extracts from DAMI cells were then incubated at 4C
with antibody-bound protein A beads. The resulting supernatant was incubated with immobilized Halo-Tag ERM 1–72 as indicated. ID:
immunodepletion. Bound (B) and unbound (U) materials were resolved by 10% SDS-PAGE before western blot analysis using the specified
antibodies. I: input, 10%. U: unbound, 10% and B: bound, 100%.
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and D) or full-length ERM (C) with (A and C) full length MED25, (B and C) MED25 ACID and MED25 VWA domains or (D) siRNA-resistant
MED25 wild-type or derivatives. Cells collected 24 h after plasmid transfections were processed for luciferase activity. The relative luciferase activity
of Gal-ERM 1–72 alone was assigned a transactivation level of 100%. Data represent the mean±S.E.M. of at least three independent transfections
performed in duplicate. (A) MED25 inhibits Gal4-ERM 1–72 transcriptional activation. Transient expression of MED25 in U2OS cells inhibits
Gal4-ERM 1–72 transactivation but not activation by Gal4-E1A 13S or Gal4-E2F. (B) MED25 ACID and VWA domains inhibit Gal-ERM 1–72
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by its murine counterpart. (Inset) The levels of expression of MED25 after transient knockdown (as monitored by western blot with an antibody
against MED25) and actin (loading control) are shown. The level of expression of the MED25 deletion mutants (western blot with anti-Flag
antibody) after transfection into U2OS cells is also shown.
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which expresses low levels of PEA3 group members (21) as
a model in which to overexpress PEA3. Expression of
PEA3 was not affected by our MED25 siRNA, indicating
the effect is specific to MED25 depletion (Figure 5A,
Inset). Interestingly, silencing MED25 did not affect sig-
nificantly ICAM-1 promoter activity or its activation by
PEA3. However, it greatly diminished the transactivation
of the MMP-1 promoter by PEA3. Importantly, similar
results were obtained with ERM and ETV1 on MMP-1
and ICAM-1 activation (Supplementary Figure S4A), but
in our hands, PEA3 was the most potent activator. This is
in accordance with previous results (39).
In a converse experiment (Figure 5B), we used siRNA
to knockdown endogenously expressed PEA3 members in
MDA-MB 231 breast cancer cells (21). Consistent with the
results in MCF-7 cells (Figure 5A), selective inhibition of
individual PEA3, ERM and ETV1 in MDA-MB 231 cells
resulted in significant but moderate reduction of MMP-1
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Figure 5. MED25 mediates PEA3-dependent target gene expression. (A) Silencing MED25 down-regulates the induction of MMP-1 mRNA by
PEA3 in MCF-7 cells. RNA from cells transfected with control (Ctrl), control and MED25-specific siRNA (Ctrl+si MED25), PEA3 (PEA3) and
PEA3 and MED25-specific siRNA (PEA3+si MED25) was subjected to RT-qPCR. Relative expression levels were calculated using the Ct method
using expression of GAPDH mRNA as a reference gene. Values are plotted relative to control set to 1. Data represent the mean±S.E.M. of at least
four independent transfections performed in duplicate. (Inset) The knockdown of endogenous MED25 and the expression of Flag-PEA3 were
confirmed by western blot. (B) Effect of siRNA-mediated ETVs and MED25 depletion on MMP-1 expression in MDA-MB 231 cells. Data
points are the average of three independent experiments. Error bars show standard deviation. (C) Effect of ETVs and MED25 depletion on
Mediator occupancy at the MMP-1 promoter. ChIP experiments were performed using antibodies against MED1 and MED18 (ChIP MED) or
IgG (ChIP Ctrl). ChIP/Input is average from two biological replicates. Error bars show standard deviation. Statistical significance was determined in
paired Student’s t-tests (*P< 0.05).
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expression (Supplementary Figure S4B). Interestingly,
the most effective down-regulation of MMP-1 expres-
sion was achieved when all three PEA3 members were
inhibited (Figure 5B and Supplementary Figure S4B).
Thus our data suggest that there is functional redundancy
among the three PEA3 factors with regard to MMP-1
regulation.
To finally explore the mechanistic relationship between
the PEA3 group members and MED25, we used ChIP
using antibodies against Mediator subunits MED1 and
MED18 to monitor Mediator recruitment to the
MMP-1 promoter in vivo (Figure 5C). In agreement with
the above results, we observed Mediator complex at the
MMP-1 promoter when MDA-MB 231 cells were trans-
fected with control siRNA. Notably, depletion of MED25
levels or depletion of ERM, PEA3 and ETV1 levels
reduced the Mediator ChIP signal, suggesting that the
PEA3 members recruit Mediator to the MMP-1
promoter in a MED25-dependent manner (Figure 5C).
Collectively, these data suggest that the PEA3 group
members may play an important functional role in recruit-
ing the Mediator complex to the MMP-1 gene.
DISCUSSION
During the past two decades, extensive efforts have been
invested in identifying the targets of transcriptional acti-
vators within the transcriptional machinery. There is now
considerable evidence that the Mediator is a bona fide
target of many transcription factors (12,40). Interactions
usually occur between TADs and one or more Mediator
subunits. For example, the N-terminal TAD of p53 binds
directly to MED17 (41,42), while the SREBP TAD
recruits the MED15 subunit (43). In this manuscript, we
have extended this list to the TAD of the PEA3 group
members by demonstrating its ability to recruit the
Mediator complex through the MED25 subunit.
Analysis of point mutations in the ERM TAD resulted
in significant loss of transactivating activity, which
correlated with loss of Mediator interaction, suggesting
that the transactivating activity of ERM and physical
contact with the Mediator are linked.
Several transactivators have been shown to interact
with MED25, such as the viral proteins VP16 (14,15),
Lana-1 (16), IE62 (17) and the nuclear receptors RARa
(18) and HNF4a (19). In light of these previous findings, it
appears that the MED25 ACID/PTOV domain possesses
a unique ability to preferentially target acidic TADs. This
connection is further supported by our finding that the
TAD of the PEA3 members directly interacts with this
domain. However, to our knowledge, PEA3 represents
the first example of a cellular gene-specific human tran-
scription factor that interacts physically and functionally
with the MED25 ACID/PTOV domain.
The findings presented here, as well as those of previous
studies (14,15,17,31,32,44), allow us to make comparisons
between three unrelated acidic TADs bound to a common
target. In both the VP16/MED25 (31,32) and the IE62/
MED25 complexes (44), a hydrophobic residue makes
crucial contacts with the MED25 ACID/PTOV domain.
Interestingly, a similar situation is observed with the
TADs of p53, EKLF and Gcn4 in which hydrophobic
residues nucleate binding to partner proteins (45–48).
These findings illustrate how transactivators have
evolved to target specific binding sites on cofactors using
a small set of critical residues (49). Remarkably, the ERM
mutant (F47L) is not only severely impaired in its ability
to interact with MED25 but also showed compromised
transactivation ability, confirming previous conclusions
(3). Thus, the simplest explanation is that the interaction
with MED25 is central to the ability of ERM to activate
gene expression. Consistent with this result, we observed
that the ERM-binding domain on MED25 (the ACID/
PTOV domain) inhibits ERM transactivation via compe-
tition. We also found that the overexpression of the
MED25 VWA domain significantly reduced the transcrip-
tional activity of ERM. This observation is in accordance
with a previous report showing the involvement of this
domain for interaction of MED25 with Mediator (14).
Our study also points to another similarity between
VP16, IE62 and PEA3 factors in binding to MED25 as
they share the same binding site on the ACID/PTOV
domain. The finding that mutation of Gln451 to
glutamic acid (Q451E) abolished not only the binding of
MED25 to ERM but also to VP16 (31) substantiates this
conclusion. This is further supported by the observation
that mutations across amino acids 447–450 of MED25
decreased IE62 binding to MED25 (44). Despite these
similarities, there are also some significant differences
between the results obtained with the three TADs.
Unlike the VP16 TAD, which contains two subdomains
H1 and H2 that can transactivate independently (33,50),
the minimal IE62 (44) and ERM TADs appear to encom-
pass a single domain. Moreover, although VP16 has been
found to directly interact with not only MED25 but also
MED17 (41) and MED15 (51), we have no evidence that
ERM can directly target other Mediator subunits (data
not shown). That is, we observed no decrease in relative
MED1, MED6, MED14 and MED24 expression by
western blot after incubation with ERM 1–72. This con-
clusion is further supported by the fact that the ERM
mutation, which ablates interaction with MED25, also
results in loss of capture of other Mediator subunits. We
also noted that the stoichiometry of MED25, MED1,
MED6, MED14 and MED24 recruitment by ERM
is 10:1:1:1:1, respectively. This is in accordance with
previous reports showing that MED25 is loosely
(variably) associated with the Mediator (52–54). We thus
propose that ERM recruits both Mediator-containing
MED25 and MED25 in its free form. The existence
of a free MED25 function (Mediator independent)
remains to be assessed and will be the subject of future
investigations.
Sequence comparisons indicate that the N-terminal
TAD of the PEA3 group members is highly conserved
(2,37). It is thus not surprising that ERM, PEA3, ETV1
and its splice variant ER81 are all capable of binding to
MED25. Accordingly, we observed that RNAi-mediated
MED25 depletion inhibited PEA3-driven expression of
MMP-1 gene transcription but surprisingly not PEA3-
induced ICAM-1 expression. The involvement of
Mediator in the context of full-length PEA3-driven
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expression of MMP-1 was confirmed by ChIP experi-
ments. A positive requirement for MED25 is further
substantiated by our findings that MED25 depletion
diminished Mediator recruitment at the MMP-1
promoter. We noticed that the MED25-PEA3 members
interaction may not be solely responsible for Mediator
recruitment because inhibition of their expression
resulted in only a 50% reduction in MMP-1 expression
and partial decrease in Mediator binding at the MMP-1
promoter. While these results do not rule out a direct role
for MED25 in PEA3 target gene activation, they suggest
the existence of a MED25-independent PEA3 regulation.
This selectivity of MED25 action is reminiscent of the
reported Mediator-dependent and -independent regula-
tion by NF-kB p65 (MED17) and nuclear receptors
(MED1) in mammals (55,56). Alternatively, the
Mediator may also be recruited to PEA3 target genes
through direct interactions with other DNA-binding tran-
scription factors and/or coactivators that act synergistic-
ally with the PEA3 group members on specific genes. For
example, the steroid receptor coactivator AIB1/SRC-3,
which indirectly recruited the Mediator (57), has been
shown to function cooperatively with PEA3 (38).
Similarly, the PEA3 factors crosstalk with nuclear recep-
tors such as the androgen receptor (58) and the oestrogen
receptor beta (59), which are known to recruit the
Mediator via MED1 (60). The functional importance of
these potential alternative pathways for Mediator recruit-
ment by the PEA3 factors remains to be established.
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Supplementary Figures 1–4.
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